Shares of Bluebird bio (BLUE) are under pressure on Tuesday after the company announced it has placed its Phase 1/2 and Phase 3 studies of LentiGlobin gene therapy for sickle cell disease on a temporary suspension due to a reported unexpected serious adverse reaction of acute myeloid leukemia. Following the news,… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3248222/-Bluebird-bio-slides-after-pausing-sickle-cell-studies)